CoChat

Anti-inflammatory effects of GLP-1 in patients with COVID-19

Open access
Sazgarnejad, Saharnaz, Yazdanpanah, Niloufar, Rezaei, Nima · 2022 · Expert Review of Anti-infective Therapy

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

INTRODUCTION: Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is awell-known glucose-lowering agent with anti-inflammatory effects. AREAS COVERED: Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1 RA, SARS-CoV-2, COVID-19, inflammation, in April2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications are discussed. However, GLP-1 is degraded by DPP-4 with aplasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings. EXPERT OPINION: Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14787210.2021.1964955

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 93 · Cited by 21

Research works printed but not linked: 6

  1. He XW, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, 48, 456
  2. Sachdeva S, 2020, SN Compr Clin Med, 6, 1
  3. Kumar R, 2020, ERJ Open Res, 4
  4. Akella A, 2013, Indian J Exp Biol, 51, 5
  5. Patoulias D, 2021, Rev Clin Esp, 27
  6. Anna R, 2021, Diabetes Care

Metadata

Authors
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N.
Affiliations
Universal Scientific Education and Research Network (IR)
Corresponding author
Rezaei, Nima
Venue
Expert Review of Anti-infective Therapy
Published
2021-08-12
Volume
20
Issue
3
Pages
373-381
ISSN
  • 1478-7210 (ISSN-L)
  • 1744-8336
OpenAlex
W3189416067
Cited by
21
References
93
Citations by year
2025: 2 · 2024: 8 · 2023: 2 · 2022: 7 · 2021: 2
FWCI
0.56
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Anti-infective Therapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, SARS-CoV-2, GLP-1 receptor agonists, anti-inflammatory activity, inflammation, dipeptidyl peptidase IV, drug repurposing, risk factors
MeSH terms
SARS-CoV-2, COVID-19 Drug Treatment, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Inflammatory Agents, Humans, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-inflammatory effects of GLP-1 in patients with COVID-19. https://app.cochat.ai/papers/10.1080/14787210.2021.1964955
The paper
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022). Anti-inflammatory effects of GLP-1 in patients with COVID-19. Expert Review of Anti-infective Therapy. https://doi.org/10.1080/14787210.2021.1964955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.